Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Roivant Sciences Ltd. (ROIV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.53+0.28 (+3.86%)
At close: 04:00PM EST
7.63 +0.10 (+1.33%)
After hours: 04:41PM EST
Advertisement

Roivant Sciences Ltd.

11-12 St. James’s Square
15th Floor 11-12 St. James’s Square
London SW1Y 4LB
United Kingdom
44 4412 955 950
https://roivant.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees620

Key Executives

NameTitlePayExercisedYear Born
Mr. Vivek RamaswamyFounder & Exec. Chairman511.8kN/A1985
Mr. Matthew GlineCEO & Director813.55kN/A1984
Dr. Eric Venker M.D., Pharm.D.Pres & COO813.55kN/A1987
Dr. Mayukh Sukhatme M.D.Pres & Chief Investment OfficerN/AN/A1976
Mr. Richard PulikChief Financial OfficerN/AN/A1979
Ms. Rakhi KumarChief Accounting OfficerN/AN/A1980
Mr. Josh ChenGen. CounselN/AN/AN/A
Ms. Marianne L. RomeoHead of Global Transactions & Risk ManagementN/AN/A1968
Woody Sherman Ph.D.Chief Computational ScientistN/AN/AN/A
Mr. Alex GasnerExec. VP of Roivant HealthN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Corporate Governance

Roivant Sciences Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement